Glaukos Corporation (GKOS) Tops Q2 EPS by 1c; Offers FY23 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Glaukos Announces Second Quarter 2023 Financial Results
August 2, 2023 4:05 PM EDTALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2023. Key highlights include:
Net sales of $80.4 million in Q2 2023 increased 11% year-over-year. Glaucoma net sales of $61.9 million in Q2 2023 increased 10% year-over-year. Corneal Health net sales of $18.5 million in Q2 2023 increased 11% year-over-year. Gross margin of approximately 75% and non-GAAP gross margin of approximately 82% in Q2 2023. Raised 2023 net sales... More